Clinical Trials on HER2 Overexpressing Gastric Carcinoma

Total 1189 results

RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Orum Therapeutics USA, Inc.

Recruiting

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

HER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

United States
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression

United States
Jin-Hee Ahn
Asan Medical Center

Unknown

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor (BIOs-Her)

HER-2 Gene Amplification | HER-2 Protein Overexpression
QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
QuantumLeap Healthcare Collaborative
Byondis B.V.

Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Ovarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditions

United States
Novartis Pharmaceuticals

Completed

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma | HER2 + Breast Cancer | HER2 + Gastric Cancer

Taiwan, Spain, Canada, Korea, Republic of, United States
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
Henan Cancer Hospital
Rongchang Biopharmaceutical; Zhengda Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

HER2-positive Gastric Cancer | Advanced Gastric Carcinoma

China
West German Study Group
Sanofi; Amgen

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing

Germany
Lin Chen

Recruiting

Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer

Efficacy | Safety | HER2 Negative | Locally Advanced Gastric Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
The Affiliated Hospital of Qingdao University

Recruiting

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Gastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line Therapy

China
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (INTEGA)

Gastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric Cancer

Germany
Morten Mau-Sørensen
Odense University Hospital; Aarhus University Hospital; Aalborg University Hospital

Recruiting

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (HERES)

Esophageal Squamous Cell Carcinoma | HER-2 Gene Amplification | HER-2 Protein Overexpression

Denmark
Triumvira Immunologics, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

HER2 Positive Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States, Canada
Silverback Therapeutics

Terminated

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Colorectal Cancer | HER2-expressing Non-small Cell Lung Cancer

United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Memorial Sloan Kettering Cancer Center

Completed

Imaging With a New Agent That Finds a Cancer Protein Called HER2

HER2-positive Carcinoma | HER2-positive Primary Malignancy

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
Changhoon Yoo

Completed

Trastuzumab in HER2-positive Biliary Tract Cancer (BILHER)

Cholangiocarcinoma | Biliary Tract Cancer | HER-2 Gene Amplification | HER-2 Protein Overexpression

Korea, Republic of
Centre Hospitalier Universitaire de Besancon

Completed

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients (TandHER)

Metastatic Cancer | HER2-positive Gastric Cancer | Docetaxel | Trastuzumab

France
Yu jiren

Recruiting

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric Cancer | Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction

China
Amsterdam UMC, location VUmc
AstraZeneca

Recruiting

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study (HER Image)

Breast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Cancer

Netherlands
Cogent Biosciences, Inc.

Terminated

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Solid Tumor | HER-2 Protein Overexpression

United States
Mersana Therapeutics

Recruiting

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast Cancer

United States
Shen Lin
RemeGen Co., Ltd.

Not yet recruiting

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Advanced Solid Tumor | Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma | HER2

China
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
Precirix

Active, not recruiting

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment

United States, Canada
Peking University

Not yet recruiting

Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System

HER2 Positive Gastric Cancer

China
Ruijin Hospital

Recruiting

ctDNA Screening in Advanced HER2 Positive Gastric Cancer

HER2-positive Gastric Cancer

China
Seoul National University Hospital
Pfizer

Completed

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer (PF299804-AGC)

Advanced Gastric Cancer | HER2

Korea, Republic of
Jagiellonian University

Completed

Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma

HER2 Negative Gastric Cancer
Qilu Hospital of Shandong University

Not yet recruiting

First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer (RCTS)

HER2-positive Gastric Cancer

China
Yonsei University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

HER2-positive Gastric Cancer

Korea, Republic of
Shengjing Hospital

Recruiting

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

HER2-positive Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

HER2 Positive Gastric Cancer

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

China
Kangbuk Samsung Hospital

Recruiting

Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)

HER2-positive Advanced Gastric Cancer

Korea, Republic of
Peking University

Recruiting

Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer

HER2 Positive Advanced Gastric Cancer

China
Ruijin Hospital

Recruiting

Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer

HER2-negative Advanced Gastric Cancer

China
Shanghai East Hospital

Recruiting

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Gastric Cancer | HER2-low-expressing Gastric Cancer

China
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina

Clinical Trials on HER2 Overexpressing Gastric Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations